Media Thread, page-11791

Respectfully I don’t believe that IMU can nor should be marketing its medication yet. I am sure FDA and TGA rules preclude it given that there is actually no available medication to market. My comments have been restricted to awareness of trial medication for trials only.
So I am unsure what IMU can actually actively do itself in the public domain other than pieces on what it is developing and in turn comment on what others invite them to comment on. Even then they must be careful not to overstate until they have the relevant approvals. Even patients are under binders of confidentiality so they are usually restricted in what they are allowed to say. Once key approvals are obtained the marketing machine will engage in distinct power. This article is likely to have been driven by the patient and /or the guy who has the group supporting similar cancers and less likely IMU at this point.